---
title: LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED
  BY RESIDUAL DISEASE STATUS IN MYELOMA
date: '2023-07-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37506339/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230729181011&v=2.17.9.post6+86293ac
source: Blood
description: From November 2014 to May 2017, 332 patients homogeneously treated with
  VRD induction, ASCT and VRD consolidation were randomized to receive maintenance
  therapy with RD (161 patients) vs IRD (171 patients). RD consisted of lenalidomide
  15 mg/d from days 1-21 plus dexamethasone 20 mg/d on days 1-4 and 9-12 at 4-weeks
  intervals while in the IRD arm oral ixazomib at a dose of 4 mg on days 1,8, and
  15 was added. MRD negative patients after 24 cycles were discontinued while those
  who were ...
disable_comments: true
---
From November 2014 to May 2017, 332 patients homogeneously treated with VRD induction, ASCT and VRD consolidation were randomized to receive maintenance therapy with RD (161 patients) vs IRD (171 patients). RD consisted of lenalidomide 15 mg/d from days 1-21 plus dexamethasone 20 mg/d on days 1-4 and 9-12 at 4-weeks intervals while in the IRD arm oral ixazomib at a dose of 4 mg on days 1,8, and 15 was added. MRD negative patients after 24 cycles were discontinued while those who were ...